CA-VEEVA-SYSTEMS-INC.
Accelerating clinical research is a top priority across sites, sponsors, and CROs. To help speed research, more sites are using Veeva SiteVault Free for managing study documentation and collaborating remotely with study monitors. In eight months since the product has been available from Veeva Systems (NYSE: VEEV), the number of SiteVault Free customers has increased to more than 500 in over 30 countries, signaling a rapid shift among global research sites to simplify and streamline study execution.
“Sites see a tremendous opportunity to reduce the time and effort in managing regulatory binders and improve how they share study information with sponsors,” said Bree Burks, RN, MSN, vice president of site strategy at Veeva and a former clinical research director. “We’re proud to support research sites around the world, making study execution and compliance easier so they can focus on important research and patient care.”
Veeva SiteVault eliminates manual and paper-based processes with a modern application to manage regulatory and source documentation compliant with 21 CFR Part 11 and HIPAA requirements. Capabilities such as electronic signatures, certified copy workflows, and reporting simplify compliance. With remote monitoring, sites can give study monitors secure and direct access to study binders from any location and streamline collaboration throughout every stage of source document review and verification.
Veeva SiteVault Free can be used for all trials regardless of what technology sponsors are using, as well as the site file for investigator-initiated trials. The application is free for clinical research sites and comes with full training and support.
For more information or to sign-up for SiteVault Free, visit sites.veeva.com . To learn more about remote monitoring, see a demo at sites.veeva.com/RemoteMonitoring .
What Sites are Saying About Veeva SiteVault Free
“We are reducing study activation timelines by 40%, spending half the time completing regulatory tasks, and saving tens of thousands of dollars per study with Veeva SiteVault Free,” said Justin Deck, chief clinical officer at Tilda Research. “Veeva has helped us dramatically improve the speed and efficiency of study execution for more than 50 studies across 18 different sponsors.”
“Our 4-hour in-person monitoring visits are now just 30 minutes using remote monitoring in Veeva SiteVault Free,” said Charles Sydnor, project manager at Crofoot Research Center. “The simplicity of the application makes it easy to collaborate remotely with study monitors. There’s also less administrative burden to maintain compliance, allowing our team to spend more time on patient care.”
“COVID-19 halted onsite visits just as we were in the process of locking our study database,” said Hanna Voltattorni, senior project manager at CNS, the largest clinical research provider in southern California. “Veeva allowed us to continue working with study monitors and keep the trial going. We are now using Veeva SiteVault Free across all our studies.”
“Veeva’s support and site-centric approach has streamlined our study processes and made operations much more efficient,” said Megan Ford, executive director, clinical trials at the Ingham Institute for Applied Medical Research. “We have now standardized on Veeva SiteVault Free across our research departments in all hospitals to simplify and streamline research.”
About Veeva SiteVault
Veeva SiteVault reduces the administrative burden of managing regulatory and source documents across all trials with capabilities such as remote monitoring, electronic signatures, certified copy workflows, and reporting. Available in two editions, SiteVault Free comes with full training and support, and SiteVault Enterprise provides customized reports, tailored workflows, and open APIs for integrations. For more information about Veeva SiteVault or to sign-up for SiteVault Free, visit sites.veeva.com
.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu
.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov
. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace Signs MoU with Ethiopian Company to Address Social Challenges through the Utilization of Satellite Data15.1.2026 07:30:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” has made a Memorandum of Understanding (MoU) with Jethi Software Development PLC (“Jethi”), an Ethiopian technology company, to cooperate on addressing social and development challenges through the utilization of satellite-based Earth observation (EO) data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114413353/en/ Naol Debele, Chief Executive Officer of Jethi (left), and Yuya Nakamura, President and CEO of Axelspace, at the signing ceremony on January 13 in Ethiopia The MoU was signed by Naol Debele, Chief Executive Officer of Jethi, and Yuya Nakamura, President and CEO of Axelspace. The signing ceremony, held in Ethiopia on January 13 (local time), was attended by representatives of the Space Science and Geospatial Institute (SSGI) of Ethiopia, members of the Jethi Bo
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
